2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.Peer-Reviewed Original ResearchConceptsPrimary peritoneal cancerPeritoneal cancerPredictive biomarkersDay 1Taxane-resistant ovarian cancerPhase II trialM2 days 1Bevacizumab 10Evaluable patientsPrior bevacizumabWeekly ixabepiloneII trialPrimary endpointSecondary endpointsRefractory statusTUBB3 expressionPrior receiptSubgroup analysisClinical trialsOvarian cancerIxabepilonePFSCancerBevacizumabPatients
2020
372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Santin A, Vergote I, Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Walter A, Childs B, Elbi C, Bulat I. 372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. International Journal Of Gynecological Cancer 2020, 30: a154-a154. DOI: 10.1136/ijgc-2020-igcs.322.Peer-Reviewed Original ResearchPlatinum-resistant ovarian cancerProgression-free survivalObjective response rateMedian progression-free survivalPLD combinationAdverse eventsMesothelin expressionClinical activityAnti-mesothelin monoclonal antibodyHigh mesothelin expressionObserved clinical activityPegylated-liposomal doxorubicinSafety/tolerabilityPrimary peritoneal cancerPhase III studyHigh medical needAnetumab ravtansineCentral immunohistochemistryEvaluable patientsExploratory subsetPeritoneal cancerIII studyMedian durationPartial responsePrior linesFinal results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
Matulonis U, Shapira R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Wu H, Keefe S, Stein K, Ledermann J. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Journal Of Clinical Oncology 2020, 38: 6005-6005. DOI: 10.1200/jco.2020.38.15_suppl.6005.Peer-Reviewed Original ResearchRecurrent advanced ovarian cancerAdvanced ovarian cancerPD-L1 expressionECOG PS 0Prior chemotherapy linesCohort AChemotherapy linesMedian OSPS 0Ovarian cancerFront-line platinum-based therapyAdvanced recurrent ovarian cancerHigh PD-L1 expressionHigh-grade serous diseaseProtocol-specified final analysisTumor PD-L1 expressionTreatment-related AEsPrimary peritoneal cancerRecurrent ovarian cancerTreatment-free intervalTreatment-related deathsModest antitumor activityModest clinical activityNew safety signalsPrimary study endpoint
2018
Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
Bulat I, Moore K, Haceatrean A, Chung J, Rajagopalan P, Xia C, Laurent D, Childs B, Santin A. Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal Of Clinical Oncology 2018, 36: 5571-5571. DOI: 10.1200/jco.2018.36.15_suppl.5571.Peer-Reviewed Original Research